Back grey_arrow_rt.gif
 
Archived NATAP Articles from July 2003
 
null.gif
 
 
  1. Viral Response to Peginterferon plus Ribavirin in Co-infection - (7/24/03)

    2.  
  2. Antiretrovirals in First Line regimens: Trizivir, Sustiva, quad vs Triple therapy, Induction-Maintenance Reported by Dr Graeme Moyle, Chelsea & Westminster Hospital, London. - (7/24/03)

    3.  
  3. Efavirenz (EFV) Well Tolerated: IAS Report - (7/24/03)

    4.  
  4. IAS - Efavirenz (EFV) Well Tolerated: IAS Report Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/23/03)

    5.  
  5. IAS - Recombinant Human Growth Hormone (r-hGH) Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/22/03)

    6.  
  6. IAS - 10% Rate of HIV Drug Resistance in Newly Infected: genotype resistance testing suggested for newly infected - (7/21/03)

    7.  
  7. IAS - Tenofovir: methadone & ribavirin interaction studies, and renal toxicity in 2 cases - (7/21/03)

    8.  
  8. IAS - Trizivir-Efavirenz Induction-Maintenance Study - (7/21/03)

    9.  
  9. IAS - Kaletra Update: Kaletra+Tenofovir+3TC Once Daily Study; Updated PHHS Guidelines on Preferred Regimens for First-Line Therapy - (7/21/03)

    10.  
  10. PHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents PDF - (7/21/03)

    11.  
  11. New HIV Treatment Guidelines Focus on "Preferred" Regimens PDF
    07/18/03

  12. IAS - Fuzeon Story: new 48 week study results; 24-week results hold up at week 48 - (7/17/03)

    13.  
  13. IAS - Does Early HCV Kinetics Predict Response to Peginterferon and Ribavirin HCV Therapy among HIV Co-infected Individuals - (7/17/03)

    14.  
  14. IAS - Reyataz+ritonavir vs Kaletra in treatment-experienced - (7/16/03)

    15.  
  15. IAS - SPD754: new NRTI, early study results - (7/16/03)

    16.  
  16. IAS - FTC: 60 week study results - (7/16/03)

    17.  
  17. IAS - Fuzeon (T-20) Story - (7/15/03)

    18.  
  18. IAS - ABC/AZT/3TC vs Efavirenz Based Regimens: ACTG 5095 - (7/14/03)

    19.  
  19. IAS - High Viral failure Rates with Abacavir/3TC/Tenofovir Once Daily Regimen - (7/14/03)

    20.  
  20. Report from The 4th International Workshop on Clinical Pharmacology of HIV Therapy - (7/14/03)

    21.  
  21. STATE AIDS DIRECTORS, PHARMACEUTICAL COMPANIES JOIN IN $50 MILLION PLAN TO ASSIST ADAPs - (7/10/03)

    22.  
  22. Lipo - Switch to Abacavir Improves Fat Loss; Experimental Uridine Study Improves Mitochondrial Toxicity in Vitro - (7/10/03)

    23.  
  23. Lipo - Atazanavir: Evaluation of Body Changes and Lipids/Glucose After 48 weeks Treatment - (7/10/03)

    24.  
  24. Lipo - Rosiglitazone For Lipoatrophy: mixed results - (7/9/03)

    25.  
  25. Lipodystrophy Workshop - (7/8/03)

    26.  
  26. EASL - COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL - (7/7/03)

    27.  
  27. EASL - Pegasys News: 4 year follow-up; study of treating cirrhotics; study of Peg-Intron non-responders - (7/7/03)

    28.  
  28. EASL - Entecavir, new HBV drug, Suppresses Lamivudine Resistance - (7/7/03)

    29.  
  29. Hepatitis C virus infection and incident type 2 diabetes - (7/7/03)

    30.  
  30. HIV Infection-A Risk Factor for Osteoporosis - (7/7/03)

    31.  
  31. Bone Mass in HIV-Infected Patients: Focus on the Role of Therapy and Sex - (7/7/03)

    32.  
  32. Hepatitus C Therapeutic Vaccine: study data released - (7/7/03)

    33.  
  33. FDA Approves New HIV Drug FTC, emtricitabine - (7/3/03)

    34.  
  34. Reyataz (atazanavir) in These Pharmacies - (7/3/03)

    35.  
  35. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma - (7/3/03)

    36.  
  36. Hispanics & HIV Testing - (7/2/03)

    37.  
  37. HIV and African Americans & Hispanics & Women - (7/2/03)

    38.  
  38. Regulation of CC chemokine receptor 5 in Hepatitis G virus infection - (7/2/03)

    39.